An update from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) is now available.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced the approval of its investigational new drug application for SKB107, a novel radionuclide-drug conjugate developed in collaboration with the Affiliated Hospital of Southwest Medical University. This approval by the National Medical Products Administration marks a significant step in the company’s efforts to advance treatments for bone metastases in solid tumors, potentially enhancing its position in the biopharmaceutical industry. However, the company cautions that the successful development and commercialization of SKB107 are not guaranteed, advising stakeholders to exercise caution.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a joint stock company based in China, specializing in the biopharmaceutical industry. The company focuses on developing innovative drug therapies, including radionuclide-drug conjugates, for the treatment of various medical conditions.
YTD Price Performance: 59.58%
Average Trading Volume: 370,792
Technical Sentiment Signal: Sell
Current Market Cap: HK$58.07B
See more insights into 6990 stock on TipRanks’ Stock Analysis page.